10-Q: Gyre Therapeutics Q3 2025: Revenue Surges, New Drugs Drive Growth

Gyre Therapeutics reports a significant increase in Q3 2025 revenue and net income, driven by successful new product launches and strong ETUARY sales.

Summary

• Net income for the three months ended September 30, 2025, was $5.9 million, a 108% increase from $2.9 million in the same period of 2024.
• Net income attributable to common stockholders for Q3 2025 was $3.6 million, up 221% from $1.1 million in Q3 2024.
• Revenues for the three months ended September 30, 2025, reached $30.6 million, a 20% increase from $25.5 million in Q3 2024.
• For the nine months ended September 30, 2025, revenues were $79.4 million, a 2% increase from $77.9 million in the prior year.
• Cash and cash equivalents significantly increased to $40.4 million as of September 30, 2025, from $11.8 million at December 31, 2024.
• The accumulated deficit decreased to $66.7 million as of September 30, 2025, from $73.5 million at December 31, 2024.
• The company successfully launched two new products: Contiva (avatrombopag maleate tablets) in March 2025 and Etorel (nintedanib, ethanesulfonate soft capsules) in June 2025.
• The pivotal Phase 3 trial of Hydronidone in the PRC for liver fibrosis in patients with chronic hepatitis B met its primary endpoint, showing statistically significant 1-stage regression in liver fibrosis (P=0.0002).
• Post-period, on November 7, 2025, Etorel was selected in the National Healthcare Security Administration's (NHSA) National Centralized Drug Procurement.

Sentiment

Score: 7

Explanation: While nine-month net income shows a decline primarily due to a non-cash warrant liability adjustment from the prior year, the third quarter demonstrates strong growth in revenue and net income, driven by successful new product launches and strategic marketing adjustments. Positive clinical trial results for Hydronidone and Etorel's inclusion in national procurement are significant positive developments, indicating strong future potential and improved market positioning. The company's liquidity has also significantly improved.

Positives

• Q3 2025 net income increased by 108% to $5.9 million, demonstrating strong profitability growth.
• Q3 2025 revenue grew by 20% to $30.6 million, driven by new product launches and a strategic refocus on ETUARY sales.
• Successful commercialization of Contiva (March 2025) and Etorel (June 2025) is contributing meaningful revenue growth.
• Hydronidone's Phase 3 trial in the PRC met its primary endpoint with statistically significant liver fibrosis regression (P=0.0002) and was well tolerated.
• Etorel's selection in the National Centralized Drug Procurement on November 7, 2025, indicates potential for broader market access and increased sales volume.
• Cash and cash equivalents increased substantially to $40.4 million as of September 30, 2025, from $11.8 million at December 31, 2024, improving liquidity.
• The accumulated deficit decreased by $6.75 million to $66.7 million, reflecting improved financial performance.
• Net cash provided by operating activities for the nine months ended September 30, 2025, was $6.6 million, a significant improvement from cash used in operating activities of $0.9 million in the prior year.

Negatives

• Net income attributable to common stockholders for the nine months ended September 30, 2025, decreased by 45% to $6.75 million compared to $12.184 million in 2024.
• Total net income for the nine months ended September 30, 2025, decreased by 35% to $11.246 million compared to $17.329 million in 2024.
• Income from operations for the nine months ended September 30, 2025, decreased by 27% to $11.369 million compared to $15.498 million in 2024.
• ETUARY sales for the nine months ended September 30, 2025, declined by $4.4 million, attributed to initial marketing resource allocation towards new product launches and market uncertainties.
• Significant customer concentration risk exists, with Sinopharm Group Co., Ltd. accounting for approximately 50.6% of total revenue for Q3 2025 and 50.3% of accounts receivable as of September 30, 2025.
• The company is exposed to foreign currency risk as a substantial portion of its cash and deposits are denominated in RMB, which is not a freely convertible currency.

Risks

• Dependence on key individuals for business operations and strategic direction.
• Competition from larger and established pharmaceutical companies with greater resources.
• Uncertainty of clinical trial results and the ability to obtain regulatory approvals for product candidates.
• Ability to obtain adequate financing to support growth and future research and development activities.
• Ability to attract and retain additional qualified personnel to manage anticipated growth.
• General economic conditions, including inflation, may adversely affect business and financial performance.
• Concentration of credit risk with cash and deposits held at commercial banks in excess of government-insured limits (PRC DIS and FDIC).
• Concentration of customer risk, with a single customer (Sinopharm Group Co., Ltd.) representing over 50% of revenue and accounts receivable.
• Foreign currency risk due to the RMB not being freely convertible and subject to central government policies.
• Exposure to claims and legal proceedings arising in the ordinary course of business, which can incur defense and settlement costs and divert management resources.
• Future capital requirements for the Hydronidone MASH-associated liver fibrosis Phase 2 trial are uncertain and may necessitate raising additional capital.
• Risks associated with the timing, progress, cost, and results of clinical trials, preclinical studies, and other R&D activities.
• Challenges in obtaining and maintaining marketing approvals for products and ensuring quality systems standards.
• Risks related to commercialization efforts, including market access, physician education, and patient support programs.
• Potential for revenue decreases due to generic entrants or health epidemics/pandemics.
• Ability to manufacture sufficient quantities of products to meet expected demand.
• Costs associated with preparing, filing, prosecuting, maintaining, and enforcing patent claims and other intellectual property rights, including potential litigation costs.
• Ability to enter into collaboration, licensing, or distribution arrangements on favorable terms.
• Potential need to expand business operations, leading to additional payroll and overhead expenses.
• Risks related to the potential in-licensing of other products or technologies.
• Emergence of competing technologies or other adverse market or technological developments.
• Restrictions under PRC laws and regulations on foreign exchange and cross-border cash transfers, limiting the ability to distribute earnings to parent companies and U.S. stockholders ($66.4 million restricted as of September 30, 2025).
• Uncertainty regarding the future impact of the One Big Beautiful Bill Act (OBBBA) on financial statements.

Future Outlook

The company anticipates continued revenue growth for the remainder of the year, driven by the expansion of ETUARY sales and the commercialization of new products, Etorel and Contiva. A Phase 2/3 clinical trial for pirfenidone for radiation-induced lung injury is expected to initiate in Q4 2025. The company plans to file a U.S. IND for Hydronidone for MASH-associated liver fibrosis in 2026, pending regulatory feedback, and subsequently initiate a Phase 2 clinical trial. A hepatic impairment study for Hydronidone in U.S. subjects is also planned to optimize dose selection.

Management Comments

• "We continue to anticipate revenue growth over the remainder of the year, driven by the growth of ETUARY sales and supplemented by the commercialization of Etorel and Contiva in 2025."
• "We expect to continue to invest in commercialization efforts, including market access, physician education, and patient support programs, to optimize uptake and maximize the long-term value of this product." (referring to Etorel)
• "In the third quarter, Gyre refocused marketing efforts on ETUARY in response to market uncertainties related to nintedanib and avatrombopag, both of which were included in the latest national volume-based procurement catalog."
• "We expect ETUARY sales will continue to grow in the three months ended December 31, 2025 compared to the same period in 2024."
• "We believe that our existing cash and cash equivalents, cash flows from operations, and access to capital markets will be sufficient to fund our operating activities and obligations for at least the next 12 months following the filing date of this Quarterly Report and thereafter for the foreseeable future."
• "We cannot guarantee that a Phase 2 trial will be initiated or estimate the funding needed for such trial at this time, but may need to raise additional capital to fund this program." (referring to Hydronidone for MASH)

Industry Context

The company operates in the commercial-stage biotechnology sector, specializing in small-molecule anti-inflammatory and anti-fibrotic drugs for organ diseases, particularly organ fibrosis, an area with significant unmet medical needs. The successful launches of Contiva and Etorel, alongside positive Phase 3 data for Hydronidone, position the company to expand its market share in respiratory, hematologic, and potentially liver fibrosis indications. The inclusion of Etorel in China's National Centralized Drug Procurement highlights the evolving regulatory and market access landscape in China, which can lead to broader adoption but also potential pricing pressures. The strategic shift to refocus marketing on ETUARY due to market uncertainties surrounding nintedanib and avatrombopag (active ingredients in Etorel and Contiva) in national procurement underscores the dynamic competitive environment.

Comparison to Industry Standards

• Pirfenidone, the active ingredient in ETUARY, is noted as the first anti-fibrotic drug approved for idiopathic pulmonary fibrosis (IPF) in Japan, the European Union, the United States, and the Peoples Republic of China, establishing a strong historical benchmark for the company's foundational product.
• Contiva (avatrombopag maleate tablets) received U.S. FDA approval for chronic liver disease-associated thrombocytopenia (CLD-associated TCP) in May 2018, and its indication was expanded to include immune thrombocytopenic purpura (ITP) in June 2019, providing a global regulatory benchmark for its efficacy and safety profile.
• Hydronidone's pivotal Phase 3 trial in the PRC met its primary endpoint with a statistically significant proportion of patients achieving a 1-stage regression in liver fibrosis compared to placebo (P=0.0002), which represents a robust clinical outcome in a placebo-controlled setting.
• The tolerability profile of Hydronidone in its Phase 3 trial, with a comparable incidence of serious adverse events (4.88% vs. 6.45% in the placebo group) and no discontinuations due to adverse events, suggests a favorable safety profile relative to typical expectations for new drug candidates.

Corporate Governance

Legal Proceedings

• The company is currently not a party to any material legal proceedings. It may become involved in legal proceedings arising in the ordinary course of business, which could have an adverse impact due to defense and settlement costs, diversion of management resources, and reputational harm.

Related Party Transactions

• No research and development fees were paid to GNI Group during the three and nine months ended September 30, 2025, compared to $0.1 million and $0.2 million, respectively, in the same periods of 2024.
• The company had $0.2 million in other receivables from GNI Group as of September 30, 2025, and December 31, 2024, related to CPI's restructuring transaction.
• The Private Placement in October 2023 involved GNI USA purchasing 811 shares of Series X Convertible Preferred Stock and 811 Preferred Stock Warrants for $5.0 million.
• In January 2024, GNI USA converted 13,151 shares of Convertible Preferred Stock into 8,767,332 shares of common stock.
• BJContinent Pharmaceuticals Limited (BJC), the majority shareholder of Gyre Pharmaceuticals, increased its capital contribution in Gyre Pharmaceuticals by $1.28 million, increasing the company's indirect interest from 65.2% to 69.7%.

Stakeholder Impact

• Shareholders: Potential for increased share value due to strong Q3 financial performance, successful new product launches, positive clinical trial results, and improved liquidity. However, dilution occurred from the May 2025 public offering and ongoing ATM program.
• Employees: Stock-based compensation plans are in place, and there was an increase in payroll costs in selling and marketing, indicating continued investment in human capital.
• Customers: New product offerings (Contiva, Etorel) provide additional treatment options. Etorel's inclusion in national procurement may lead to broader access and affordability.
• Creditors: Improved cash position and a reduced accumulated deficit may enhance the company's creditworthiness and ability to meet financial obligations.
• Suppliers: Increased production costs for ETUARY and costs associated with new products suggest continued demand for raw materials and services from suppliers.

Next Steps

• Initiate the anticipated adaptive Phase 2/3 clinical trial for pirfenidone for radiation-induced lung injury in the fourth quarter of 2025.
• Actively engage with the NMPA to confirm Priority Review eligibility for Hydronidone's New Drug Application (NDA) and continue the submission process.
• File the U.S. IND for Hydronidone for the treatment of MASH-associated liver fibrosis in 2026, pending regulatory feedback.
• Initiate a Phase 2 clinical trial for Hydronidone for MASH-associated liver fibrosis, subject to IND clearance.
• Conduct a hepatic impairment study in U.S. subjects for Hydronidone to optimize dose selection and safe enrollment criteria.
• Continue enrolling patients in a randomized, double-blind, placebo-controlled Phase 2 clinical trial for F573 (caspase inhibitor) for acute/acute on-chronic liver failure.
• Evaluate F528 (novel anti-inflammation agent) in preclinical studies as a potential first-line therapy for chronic obstructive pulmonary disease.
• Assess the potential impact of Etorel's selection in the National Centralized Drug Procurement on future operating performance.

Key Dates

Recommendation

The company demonstrates strong operational momentum with significant Q3 revenue and net income growth, driven by successful new product launches (Contiva, Etorel) and a strategic refocus on its core product, ETUARY. The positive Phase 3 clinical trial results for Hydronidone, a key pipeline candidate, and Etorel's inclusion in China's National Centralized Drug Procurement, signal strong future market potential and regulatory progress. While nine-month net income was impacted by a non-cash warrant liability adjustment from the prior year, the underlying business performance and improved liquidity position are highly favorable. The company's ability to fund operations for the foreseeable future, coupled with a robust pipeline and expanding commercial footprint in a high-need therapeutic area, makes it an attractive investment.

Keywords

Biotechnology, Pharmaceuticals, Organ Fibrosis, IPF, Pirfenidone, ETUARY, Hydronidone, MASH, Liver Fibrosis, Contiva, Etorel, Nintedanib, Avatrombopag, Clinical Trials, New Drug Application, NMPA, SEC Filing, 10-Q, Financial Results, Revenue, Net Income, China, PRC